Loading stock data…
¥2,818-19.00 (-0.67%)
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally.
Daiichi Sankyo Company, Limited in the Healthcare sector is trading at ¥2,818 with a market capitalization of $5.1T. Wall Street consensus targets ¥4,021 (16 analysts), implying a +42.7% move over the next 12 months. The stock is currently 31% below its 52-week high of ¥4,088, remaining 1.9% above its 200-day moving average. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (JPY) · Annual | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total Revenue | ¥1.28T↓ | ¥1.60T↓ | ¥1.89T↓ | ¥2.12T |
| Gross Profit | ¥914.95B↓ | ¥1.19T↓ | ¥1.47T↑ | ¥1.45T |
| Operating Income | ¥120.58B↓ | ¥211.59B↓ | ¥331.93B↑ | ¥229.09B |
| Net Income | ¥109.19B↓ | ¥200.73B↓ | ¥295.76B↑ | ¥259.87B |
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adeno...